Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2022 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Departure of Chief Financial Officer
November 10, 2022 16:15 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the...
Ultragenyx to Present at Upcoming Healthcare Conferences
November 09, 2022 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
November 02, 2022 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
Third quarter 2022 total revenue of $90.7 million and Crysvita® revenue in Ultragenyx territories1 of $64.5 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million...
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
October 27, 2022 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx anuncia el reconocimiento de medicamento huérfano de Dojolvi® (triheptanoína) en México para el tratamiento de los trastornos de oxidación de ácidos grasos de cadena larga en adultos y niños
October 03, 2022 13:27 ET
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una empresa biofarmacéutica centrada en el desarrollo de nuevos productos para enfermedades...
Ultragenyx anuncia la aprobación de Crysvita® (burosumab) en Argentina para el tratamiento de la hipofosfatemia ligada al cromosoma X (XLH)
October 03, 2022 13:25 ET
|
Ultragenyx Pharmaceutical Inc.
BUENOS AIRES, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., una empresa biofarmacéutica centrada en el desarrollo y la comercialización de nuevas terapias para enfermedades...
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
September 09, 2022 20:22 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the...
Ultragenyx to Participate at Citi BioPharma Conference
September 01, 2022 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...